Suchergebnisse - "Rimassa, Lorenza"

PubPharm (18)

1

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : final results of a randomised phase 3 study

enthalten in: The lancet. Gastroenterology & hepatology | 2024

von Yau, T. | Kaseb, A. | Cheng, A. | +19

2

Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas : An Early Exploratory Analysis

enthalten in: Targeted oncology | 2022

von Rimini, M. | Burgio, V. | Antonuzzo, L. | +13

3

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Kelley, R. | Rimassa, L. | Cheng, A. | +19

CommentIn: Lancet Oncol. 2022 Aug;23(8):962-963. - PMID 35798015

4

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8 : a retrospective analysis of the CELESTIAL randomised controlled trial

enthalten in: BMC cancer | 2022

von El-Khoueiry, A. | Meyer, T. | Cheng, A. | +5

5

Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma : shedding light on the preclinical rationale and clinical trials

enthalten in: Expert opinion on investigational drugs | 2022

von Cammarota, A. | Zanuso, V. | D'Alessio, A. | +3

6

Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma : matching-adjusted indirect comparison analysis

enthalten in: Journal of cancer research and clinical oncology | 2021

von Casadei-Gardini, A. | Rimassa, L. | Rimini, M. | +15

7

Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Kelley, R. | Meyer, T. | Rimassa, L. | +13

8

Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma : COSMIC-312 Phase III study design

enthalten in: Future oncology (London, England) | 2020

von Kelley, R. | W Oliver, J. | Hazra, S. | +4

9

Molecular therapies for HCC : Looking outside the box

enthalten in: Journal of hepatology | 2020

von Faivre, S. | Rimassa, L. | Finn, R.

10

Regorafenib in patients with refractory metastatic pancreatic cancer : a Phase II study (RESOUND)

enthalten in: Future oncology (London, England) | 2019

von Bozzarelli, S. | Rimassa, L. | Giordano, L. | +8